<DOC>
	<DOCNO>NCT01770379</DOCNO>
	<brief_summary>This study provide efficacy safety data secukinumab pre-filled syringe ( PFS ) subcutaneous self-administration patient active rheumatoid arthritis intolerant inadequate response anti-TNF-α agent .</brief_summary>
	<brief_title>Secukinumab Efficacy Safety Study Patients With Rheumatoid Arthritis Inadequate Response Anti-TNFα Agents .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>• Presence Rheumatoid Arthritis classify ACR 2010 revise criterion least 3 month •Disease activity define ≥6 tender joint 68 ≥ 6 swollen joint 66 baseline : Either AntiCCP antibody positive OR Rheumatoid Factor positive AND WITH Either hsCRP ≥ 10 mg/L OR ESR ≥28 mm/1st hr •Intake least one antiTNFα agent etanercept , adalimumab , infliximab , certolizumab golimumab least 3 month enter study experience inadequate response treatment intolerant least one administration Current RA functional status class IV accord ACR 1991 revise criterion •Previous use secukinumab biologic drug directly target IL17 IL17 receptor and/or history hypersensitivity secukinumab excipient drug similar chemical class . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rheumatoid Arthritis , RA , IL-17 blocker , subcutaneous , self-injection , AIN457 , AIN457F , secukinumab , anti-TNFα , pre-filled syringe</keyword>
</DOC>